Welcome to the e-CCO Library!

P527: Body image dissatisfaction is increased in inflammatory bowel disease compared with healthy matched controls but not diseased controls
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Su*1, A. Chen1, S. Brown1, J. Alcantara1, D. Sim2, H. Myint1, P. Lilic1, S. Inns1,2

Created: Friday, 22 February 2019, 9:41 AM
P527: Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

St. Clair Jones A.*1, Smith M.2

Created: Wednesday, 20 February 2019, 10:36 AM
P527: Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry
Year: 2021
Source: ECCO'21 Virtual
Authors: Louis , E.(1);Muls , V.(20);Bossuyt , P.(2);Colard , A.(3);Nakad , A.(4);Baert , D.(5);Mana , F.(6);Caenepeel , P.(7);Vanden Branden , S.(8);Vermeire , S.(9);D'Heygere , F.(10);Strubbe , B.(11);Cremer , A.(12);Setakhr , V.(13);Baert , F.(14);Vijverman , A.(15);Coenegrachts , J.L.(16);Flamme , F.(17);Hantson , A.(18);Bennett , D.(19);Van Gassen , G.(18);Hantsbarger , G.(19);
Created: Wednesday, 2 June 2021, 4:12 PM
P527: Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tanaka, A.(1)*;Kanmura, S.(1);Maeda, N.(1);Kuwazuru, K.(1);Komaki, F.(1);Komaki, Y.(1);Ido, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P527: Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Verstockt1,2*, G. Moors1, S. Bian3, T. Van Stappen3, S. Tops3, V. Ballet1, G. Van Assche1,2, S. Vermeire1,2, A. Gils3, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
P527: Telemedicine in IBD patients: results of a national survey of the Italian IBD patients’ association (AMICI Onlus)
Year: 2022
Source: ECCO'22
Authors: Costantino, A.(1,2);Caprioli, F.(1,2);Vecchi, M.(1,2);Stocco, D.(3);Aloi, M.(4);Armuzzi, A.(5);Ficari, F.(6);Manguso, F.(7);Mocci, G.(8);Orlando, A.(9); Pironi, L.(10);Radice, S.(11);Rizzello, F.(12);Tongiorgi, A.(13);Leone, S.(14);Bossa, F.(15);
Created: Friday, 11 February 2022, 3:56 PM
P528 Response to biologic therapy in operated Crohn’s disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.C. Georgieva, A. Atanassova, M. Mirchev

Created: Thursday, 30 January 2020, 10:12 AM
P528: Effectiveness, Safety and Incremental Costs of Proactive Therapeutic Drug Monitoring of Infliximab in a Prospective Cohort of Inflammatory Bowel Disease Patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zelinkova, Z.(1)*;Podmanicky, D.(2);Kadleckova, B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P528: Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBD
Year: 2022
Source: ECCO'22
Authors: Costantino, A.(1,2);Vecchi, M.(1,2);Stocco, D.(3);Noviello, D.(4);Conforti, F.S.(1);Maregatti, M.(4);Caprioli, F.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P528: Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bastida G.*1,2, Sargalt L.3, Garcia V.4, Mesonero F.5, Braithwaite A.M.6, Montserrat A.7, Martín M.D.8, Sicilia B.9, Olivares D.10, Vicente R.11, Rodriguez E.12, Navarro P.13, Lobaton T.3

Created: Wednesday, 20 February 2019, 10:36 AM
P528: Patients’ perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: A 12-month prospective observational cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Petitdidier1*, C. Gagniere1, A.L. Rentien1, J. Tannoury1, Y. Le Baleur2, F. Mesli1, I. Sobhani1, A. Amiot1

Created: Thursday, 21 February 2019, 9:14 AM
P528: Reducing intravenous monoclonal antibody observation times without compromising patient safety; a single-centre observational study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Rees, F.(1);Packham, A.(1);Parmar, A.(1);Hills, E.(1);Smith, M.(1);St. Clair Jones, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P529 Natural history and management strategies of ulcerative colitis (UC) in a paediatric population: A 10-year review in a tertiary paediatric gastroenterology centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Sonnino, A. Ocholi, A. ElZein, E. Saliakellis, L. Pensabene, O. Borrelli, F. Kiparissi

Created: Thursday, 30 January 2020, 10:12 AM
P529: Adalimumab persistence and its biosimilar in inflammatory bowel disease: experience in a tertiary centre
Year: 2021
Source: ECCO'21 Virtual
Authors: Fernandez Cano, M.C.(1);Sánchez-Capilla, A.D.(1);Martín-Rodríguez, M.M.(1);Cabello-Tapia, M.J.(1);Redondo-Cerezo, E.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P529: Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID).
Year: 2022
Source: ECCO'22
Authors: Geldof, J.(1);Sabino, J.(2);Ferrante, M.(2);Lambert, J.(3);Lapeere, H.(3);Hillary, T.(4);Van Laethem, A.(4);De Vlam, K.(5);Verschueren, P.(5);Lobaton, T.(1);Vermeire, S.(2);
Created: Friday, 11 February 2022, 3:56 PM
P529: Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Rosario1, D. Polhamus2, N. Dirks2, R. Lock3, X. Yao1, J. Chen1, C. Chen1, W. Sun1, B. Feagan4, W. Sandborn5, G. D’Haens*6

Created: Friday, 22 February 2019, 9:41 AM
P529: Impact of stress in inflammatory bowel disease. Effect of a group psychological intervention program
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bernabeu P.1, Buades N.1, Alonso M.1, Van-der Hofstadt C.1, Gutiérrez A.*2,3, Sempere L.2, Rodríguez-Marín J.1, Jover R.2

Created: Wednesday, 20 February 2019, 10:36 AM
P529: Longer duration of vancomycin prevents recurrence of C. difficile in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Lei*, M.J. Andersen Jr., R. Weisshof, N. Meter, D.T. Rubin

Created: Thursday, 21 February 2019, 9:14 AM
P529: Year-two follow-up results of an observational study conducted in Crohn's disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life setting
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Laharie, D.(1)*;Pierron, G.(2);Brault, Y.(3);Bouhnik, Y.(4);Nancey, S.(5);
Created: Friday, 14 July 2023, 11:05 AM
P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Diakite1, B. Schultz2, J. Carter1, S. Snedecor1, R. Turpin3

Created: Thursday, 30 January 2020, 10:12 AM